Cargando…

Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest

Objectives To evaluate the efficacy of oestradiol valerate/dienogest (E(2)V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies. Methods Women aged ≥ 18 years with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, Ian S, Parked, Susanne, Mellinger, Uwe, Machlitt, Andrea, Serrani, Marco, Jensen, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: e-Century Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154543/
https://www.ncbi.nlm.nih.gov/pubmed/21774563
http://dx.doi.org/10.3109/13625187.2011.591456
Descripción
Sumario:Objectives To evaluate the efficacy of oestradiol valerate/dienogest (E(2)V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies. Methods Women aged ≥ 18 years with heavy and/or prolonged menstrual bleeding were randomised to E(2)V/DNG (n = 269) or placebo (n = 152) for 196 days. Objective changes in menstrual blood loss (MBL) volume were assessed using the alkaline haematin method. Results After six months of treatment, median MBL decreased by 88% with E(2)V/DNG compared with 24% with placebo. The greatest reduction was achieved at the first withdrawal bleed after treatment initiation and it was sustained with no loss of effect throughout treatment. Conclusion E(2)V/DNG was more effective than placebo in reducing MBL in women with heavy and/or prolonged menstrual bleeding without organic pathology. The reduction was largely achieved as early as the first withdrawal bleed, with further gradual improvement throughout treatment.